C12N 2760/18634
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/18634 (Use of virus or viral component as vaccine) appears on 118 US grants and 153 published applications in this corpus.
Search patents in C12N- Granted patents
- 118
- Published applications
- 153
- Assignees
- 93
- Inventors
- 272
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 3 | 0 |
| 1998 | 6 | 0 |
| 1999 | 4 | 0 |
| 2000 | 5 | 0 |
| 2001 | 3 | 0 |
| 2002 | 1 | 3 |
| 2003 | 1 | 6 |
| 2004 | 4 | 7 |
| 2005 | 0 | 4 |
| 2006 | 0 | 2 |
| 2007 | 2 | 6 |
| 2008 | 5 | 7 |
| 2009 | 4 | 7 |
| 2010 | 5 | 7 |
| 2011 | 4 | 5 |
| 2012 | 0 | 7 |
| 2013 | 5 | 5 |
| 2014 | 5 | 10 |
| 2015 | 2 | 4 |
| 2016 | 6 | 7 |
| 2017 | 9 | 4 |
| 2018 | 3 | 7 |
| 2019 | 7 | 3 |
| 2020 | 6 | 12 |
| 2021 | 4 | 1 |
| 2022 | 5 | 8 |
| 2023 | 3 | 6 |
| 2024 | 2 | 11 |
| 2025 | 5 | 5 |
| 2026 | 4 | 9 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/PIV3 F protein and uses thereof2 Jun 2026US 12,643,925 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Betacoronavirus mRNA vaccines19 May 2026US 12,629,412 B2ModernaTX, Inc.
- Betacoronavirus mRNA vaccines17 Feb 2026US 12,551,734 B2ModernaTX, Inc.
- Betacoronavirus RNA vaccines13 Jan 2026US 12,521,577 B2ModernaTX, Inc.
- Prefusion PIV F immunogens and their use7 Oct 2025US 12,435,113 B2Institute for Research in Biomedicine
- Prefusion-stabilized human parainfluenza virus 3 f proteins8 Oct 2026US 2026/0306613 A1Board of Regents, The University of Texas System
- Stabilized pre-fusion piv3 f proteins13 Aug 2026US 2026/0232789 A1Msd International Business GmbH
- Pre-fusion human piv1 f proteins21 May 2026US 2026/0139011 A1Janssen Vaccines & Prevention B. V.
- Anti-Viral Therapeutic Peptides, Conjugates, and Methods of Use Thereof14 May 2026US 2026/0131011 A1Decoy Therapeutics Inc.
- Betacoronavirus mrna vaccines23 Apr 2026US 2026/0108595 A1ModernaTX, Inc.
Most cited
By later US patents
- Combination PIV3/hMPV RNA vaccines110US 10,064,934 B2ModernaTX, Inc. · 2018
- Modified live BRSV vaccine77US 5,733,555 AAmerican Home Products Corporation · 1998
- Respiratory virus nucleic acid vaccines53US 11,103,578 B2ModernaTX, Inc. · 2021
- Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine50US 5,869,036 ASt. Louis University · 1999
- HMPV/hPIV3 mRNA vaccine composition47US 11,351,242 B1ModernaTX, Inc. · 2022